Lilly Xigris Phase IV Studies Will Enroll 14,000 Sepsis Patients
Lilly is committed to studying nearly 14,000 sepsis patients to meet its postmarketing obligations for its sepsis agent Xigris (drotrecogin alfa)
Lilly is committed to studying nearly 14,000 sepsis patients to meet its postmarketing obligations for its sepsis agent Xigris (drotrecogin alfa)